JP2022535108A5 - - Google Patents
Info
- Publication number
- JP2022535108A5 JP2022535108A5 JP2021571941A JP2021571941A JP2022535108A5 JP 2022535108 A5 JP2022535108 A5 JP 2022535108A5 JP 2021571941 A JP2021571941 A JP 2021571941A JP 2021571941 A JP2021571941 A JP 2021571941A JP 2022535108 A5 JP2022535108 A5 JP 2022535108A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cyclopropane
- dicarboxamide
- oxyphenyl
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856920P | 2019-06-04 | 2019-06-04 | |
| US62/856,920 | 2019-06-04 | ||
| PCT/US2020/035808 WO2020247418A1 (en) | 2019-06-04 | 2020-06-03 | Compounds for the treatment of kinase-dependent disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535108A JP2022535108A (ja) | 2022-08-04 |
| JP2022535108A5 true JP2022535108A5 (enExample) | 2023-06-12 |
| JP7820152B2 JP7820152B2 (ja) | 2026-02-25 |
Family
ID=71842789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571941A Active JP7820152B2 (ja) | 2019-06-04 | 2020-06-03 | キナーゼ依存性障害の処置のための化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12503438B2 (enExample) |
| EP (1) | EP3980404A1 (enExample) |
| JP (1) | JP7820152B2 (enExample) |
| CN (1) | CN114040912B (enExample) |
| AR (1) | AR119069A1 (enExample) |
| AU (1) | AU2020289324B2 (enExample) |
| CA (1) | CA3139156A1 (enExample) |
| MA (1) | MA56114A (enExample) |
| TW (1) | TWI850394B (enExample) |
| WO (1) | WO2020247418A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| CN114573553B (zh) * | 2022-01-27 | 2023-11-10 | 广州六顺生物科技有限公司 | 杂芳环类衍生物及其制备方法和应用 |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
| CN116271008A (zh) * | 2022-12-30 | 2023-06-23 | 广东天普生化医药股份有限公司 | 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| JP2009526761A (ja) | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| UA121655C2 (uk) * | 2014-04-25 | 2020-07-10 | Екселіксіс, Інк. | Спосіб лікування аденокарциноми легень |
| CN104817497B (zh) * | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| SG11202005719UA (en) * | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| CN117402114A (zh) | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
-
2020
- 2020-06-02 AR ARP200101554A patent/AR119069A1/es unknown
- 2020-06-03 US US17/616,120 patent/US12503438B2/en active Active
- 2020-06-03 MA MA056114A patent/MA56114A/fr unknown
- 2020-06-03 CN CN202080048050.0A patent/CN114040912B/zh active Active
- 2020-06-03 WO PCT/US2020/035808 patent/WO2020247418A1/en not_active Ceased
- 2020-06-03 EP EP20747207.7A patent/EP3980404A1/en active Pending
- 2020-06-03 AU AU2020289324A patent/AU2020289324B2/en active Active
- 2020-06-03 CA CA3139156A patent/CA3139156A1/en active Pending
- 2020-06-03 JP JP2021571941A patent/JP7820152B2/ja active Active
- 2020-06-04 TW TW109118785A patent/TWI850394B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535108A5 (enExample) | ||
| JP2013523884A5 (enExample) | ||
| CA2515197A1 (en) | Pyrazolopyridine derivates | |
| CN105209464B (zh) | P2x7调节剂 | |
| JP2016519096A5 (enExample) | ||
| JP2021138734A (ja) | 新規化合物 | |
| JP2021501220A5 (enExample) | ||
| CN114945571B (zh) | 环状化合物及其使用方法 | |
| CN115594680A (zh) | 一种tead抑制剂 | |
| JP2016514719A5 (enExample) | ||
| JP2021515036A5 (enExample) | ||
| JP2016514718A5 (enExample) | ||
| RU2017112518A (ru) | Пиридоновые и азапиридоновые соединения и способы применения | |
| JP2017530960A5 (enExample) | ||
| JP2012525395A5 (enExample) | ||
| KR20190046921A (ko) | 세포 대사 과정의 억제제 | |
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| JP2018522859A5 (enExample) | ||
| IL263511A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| JP2018510183A (ja) | Ｕｓｐ３０阻害剤としての１−シアノ−ピロリジン化合物 | |
| JP2022551422A5 (enExample) | ||
| JP2007504148A5 (enExample) | ||
| JP2014506589A (ja) | 神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン | |
| JP2011509937A5 (enExample) | ||
| JP2021501805A5 (enExample) |